Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation: Literature Review and Nursing Implications
Article Sidebar
Main Article Content
Abstract
Abstract: Graft-versus-host disease (GvHD) is one of the most complications and remains a major cause of morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell transplantation. GvHD is divided into acute and chronic GvHD.Acute GvHD generally presents with skin, gastrointestinal and liver symptoms, whereas chronic GvHD affects the whole body tissues. GvHD prophylaxis regimen is generally a calcineurin inhibitor in combination with methotrexate, while high-dose systemic steroids are used for advanced GvHD treatment. This article provides a basic overview of GvHD and presents the nurses’ roles in caring for patients with GvHD. Nurses can apply this information in their clinical practice, teaching, and education, including the topic of GvHD prevention, monitoring signs and symptoms of GvHD, and self-care in managing symptoms. Hopefully, this article could enhance the quality of nursing care and improve outcomes in allogeneic hematopoietic stem cell transplantation.
Keywords: Allogeneic hematopoietic stem cell transplantation, Graft-versus-host disease (GvHD), Literature review, Nurses’ roles,
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความ ข้อมูล เนื้อหา รูปภาพ ฯลฯ ที่ได้รับการตีพิมพ์ในรามาธิบดีพยาบาลสาร ถือเป็นลิขสิทธิ์ของวารสาร หากบุคคลหรือหน่วยงานใดต้องการนำทั้งหมดหรือส่วนหนึ่งส่วนใดไปเผยแพร่หรือเพื่อกระทำการใด ใด จะต้องได้รับอนุญาตเป็นลายลักษณ์อักษรจากรามาธิบดีพยาบาลสารก่อนเท่านั้น
References
Maziarz RT, Slater S. Blood and marrow transplant handbook: comprehensive guide for patient care. 2nd ed.New York: Springer; 2015.
Wingard JR, Gastineau DA, Leather HL, Snyder EL,Szczepiorkowski ZM. Hematopoietic stem cell transplantation: a handbook for clinicians. 2nd ed.Maryland: Association for the Advancement of Blood and Biotherapies; 2015.
Center for International Blood and Marrow Transplant Research (CIBMTR). Current uses and outcomes of hematopoietic cell transplantation (HCT) in US 2020 summary slides; 2020 [cited 2020 May 28]. Available from: http://www.cibmtr.org/ReferenceCenter/
SlidesReports/SummarySlides/Pages/index.aspx
Gatza E, Choi SW. Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation. Int J Hematol Oncol. 2015;4(3):113–26. doi:10.2217/ijh.15.13.
Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all.Blood. 2014;124(3):344-53. doi: 10.1182/blood-2014-02-514778.
Fleishhauer K. Selection of matched unrelated donors moving forward: from HLA allele counting to functional matching. Hematol-Am Soc Hemat. 2019: (1):532-8.
Tiercy J-M. How to select the best available related or unrelated donor of hematopoietic stem cells?Haematologica. 2016;101(6):680-7. doi: 10.3324/haematol.2015.141119.
Hirankarn N. Beyond HLA typing, What’s next?. Journal of Hematology and Transfusion Medicine. 2017;27(3):209-13. (in Thai)
Niparuck P. Leukemia. Bangkok: Digital ID print; 2021.(in Thai)
Maffini E, Labopin M, Blaise D, Ciceri F, Gulbas Z,Deconinck E, et al. CD34+ cell dose effects on clinical outcomes after t-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells: a study from The acute leukemia working Party of the European society for Blood and Marrow Transplantation (EBMT). Am J Hematol. 2020; 95:892-9.
Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, et al. Increasing incidence of chronic graft-versushost disease in allogeneic transplantation: a report from The Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015; 21(2):266-74. doi: 10.1016/j.bbmt.2014.10.021.
Frey NV, Porter DL. Graft-versus-host disease after donor leukocyte infusions: presentation and management. Best Pract Res Clin Haematol. 2008;21(2):205-22.doi: 10.1016/j.beha.2008.02.007.
Chevallier P, Berceanu A, Peterlin P, Garnier A, Bourgeois AL, Imbert BM, et al. Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. Acta Oncol. 2021;60(4):466-74.
doi: 10.1080/0284186X.2020.1837947.
Cordeiro IRR, Rodrigues JAP, Piubello SMN, Niero AC.Nursing care for patients with graft-versus-host disease.J Nurs UFPE online. 2021;15:e245778. doi: 10.5205/1981-8963.2021.245778.
Proenca SFFS, Machado CM, Coelho RCFP, Sarquis LMM, Guimaraes PRB, Kalinke LP. Quality of life of patients with graft-versus-host disease (GvHD) posthematopoietic stem cell transplantation. Rev Esc Enferm USP. 2016;50(6):951-8.
Hunt IV, Kilgour JM, Danby R, Peniket A, Matin RN. “Is this the GVHD” a qualitative exploration of quality of life issues in individuals with graft-versus-host disease following allogeneic stem cell transplant and their experiences of a specialist multidisciplinary bone marrow transplant service. Health Qual Life Outcomes.2021;19(1):11. doi: 10.1186/s12955-020-01651-2.
Jinagub J, Kespichayawattana J, Pudtong N. Experiences of patients receiving transplants of donated allogeneic stem cells. Thai Journal of Nursing Council. 2021;36(4):60-79. (in Thai)
Mattson MR. Graft-versus-host disease: review and nursing implications. Clin J Oncol Nurs. 2007;11(3):325-8. doi: 10.1188/07.CJON.325-328.
Cuker A, Altman JK, Gerds AT, Wun T. American society of hematology self-assessment program textbook. 7th ed.Washington: American Society of Hematology; 2019.
Chao NJ. Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease; 2021 [cited 2021 April 14]. Available from: https://www.uptodate.com/contents/clinical-manifestations-diagnosis-andgrading-of-acute-graft-versus-host-disease
Mima A, Tansho K, Nagahara D, Tsubaki K. Incidence of acute kidney disease after receiving hematopoietic stem cell transplantation: a single-center retrospective study.Peer J. 2019;e6467. doi: 10.7717/peerj.6467.
Cooke KR and Yanik G. Acute lung injury after allogeneic stem cell transplantation: Is the lung a target of acute graftversus-host disease?. Bone Marrow Transplant.2004;34:753-65.
Pellegrini M, Bernabei F, Barbato F, Arpinati M,Giannaccare G, Versura P, Bonifazi F. Incidence, risk factors and complications of ocular graft-versus-host disease following hematopoietic stem cell transplantation.Am J Ophthalmol. 2021;227:25-34. doi: 10.1016/j.
ajo.2021.02.022.
Jagasia MH, Greinix HT, Arora M, Williams KM, Daniel W, Cowen EW, et al. National Institutes of Health consensus development project on criteria for clinical trails in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389-401. doi:10.1016/j.bbmt.2014.12.001.
Woodward S. Management of faecal incontinence in graftversus- host disease. Br J Nurs. 2012; 21(2):1-4. doi: 10.12968/bjon.2012.21.2.84.
Naymagon S, Naymagon L, Wong SY, Ko HM, Renteria A, Levine J, et al. Acute graft-versus-host disease of the gut: considerations for the gastroenterologist. Nat Rev Gastroenterol Hepatol. 2017;14(12):711-26. doi:10.1038/nrgastro.2017.126.
Matsukuma KE, Wei D, Sun K, Ramsamooj R, Chen M.Diagnosis and differential diagnosis of hepatic graft versus host disease (GVHD). J Gastrointest Oncol. 2016;7(Suppl1):S21-31. doi: 10.3978/j.issn.2078-6891.2015.036.
Carreras E, Dufour C, Mohty M, Kroger N. The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies[E book]. Cham: Springer; 2019.Available from: https://www.ebmt.org/sites/default/files/2019-01/2019_Book_TheEBMTHandbook.pdf
Sriswasdi C. Prevention of graft versus host disease. Journal of Hematology and Transfusion Medicine. 2016;26(4):327-9. (in Thai)
Meeudompong U and Kaewla J. Ruxolitinib for the treatment of acute graft-versus-host disease (aGVHD).Thai Cancer Journal. 2021;41(1):49-56. (in Thai)
Hooker DS, Grabe-Heyne K, Henne C, Bader P, Toumi M. Improved therapeutic approaches are needed to manage graft-versus-host disease. Clin Drug Investig. 2021;41:929-39. doi: 10.1007/s40261-021-01087-6.
Phoodaangau B. Transition theory: its application to family nursing care. Thai Journal of Nursing Council.2013;28(3):107-20. (in Thai)
Lee SJ. Classification systems for chronic graft-versushost disease. Blood. 2017;129(1):30-7. doi: 10.1182/blood-2016-07-686642.